This repository contains the code and analysis for predicting kinase inhibitor activity using Kindel dataset (https://arxiv.org/pdf/2410.08938)
The project is structured in three parts: exploratory analysis, proof of concept (PoC), and deployment planning.
-
exploratory/
- Exploratory analysis of different featurization methods and models.
- Only data from random split 1 is used.
- Splitting, evaluation, and metrics follow the Kindel paper.
- From this analysis, the ChemBERTa+DNN model (ChemBERTa embeddings + 32-unit DNN head, fine-tuned) was selected for the PoC.
-
poc/
- Code for the PoC model (ChemBERTa+DNN).
- Includes scripts for training and prediction.
- pixi.toml defines the environment dependencies.
- Alternatively Docker image can be used.
-
deployment/
- Contains information for deploying the ChemBERTaDNN model as a production-ready system.
-
ChemBERTa+DNN outperformed all other models in the exploratory phase. Fine-tuning ChemBERTa embeddings gave the best performance overall.
-
On test datasets, all models performed worse than on validation sets (highlighting generalization issues).
-
The above conclusions are valid both for DDR1 and MAPK14 targets.
-
Leveraging pre-trained transformer embeddings can be a promising approach, as it consistently improves performance compared to traditional featurization methods.
-
However, overall predictive performance remains limited. The results indicate that the models, including ChemBERTa+DNN, still struggle to generalize to unseen compounds, especially in off-DNA test sets.
-
Limitations:
- No hyperparameter tuning or extensive architecture search was performed.
- Limited to a subset of the dataset (random split 1).
-
Opportunities for improvement:
- Explore different architectures and hyperparameters.
- Test alternative transformer models (e.g., MolFORMER) and Graph Neural Networks (GNNs).
- Incorporate biological context (e.g., protein target information).
- Evaluate across the full Kindel dataset.
- Deepen understanding of dataset properties, evaluation metrics, and biology/chemistry of the targets.
- Experiment with more architectures and featurizations.
- Enhance deployment pipeline.
- Extend experiments beyond split 1.